Cardiff Oncology (FRA:XE7C) E10: €-13.60 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XE7C Cardiff Oncology Inc FRA:XE7C
31 GF Score
Price €0.77
! 5 Warning Signs
View Full Analysis

What is Cardiff Oncology E10?

Cardiff Oncology FRA:XE7C -0.83% 31 E10 is €-13.60 as of Jun. 2026. GuruFocus rates FRA:XE7C with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cardiff Oncology's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.122. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-13.60 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 20.50% per year. During the past 5 years, the average E10 Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cardiff Oncology was 20.50% per year. The lowest was 6.60% per year. And the median was 12.40% per year.

As of today (2026-08-16), Cardiff Oncology's current stock price is €0.773. Cardiff Oncology's E10 for the quarter that ended in Jun. 2026 was €-13.60. Cardiff Oncology's Shiller PE Ratio of today is .


Cardiff Oncology  (FRA:XE7C) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cardiff Oncology E10 Related Terms


Cardiff Oncology E10 Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology E10 Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.86 -41.45 -35.68 -32.16 -20.16

Cardiff Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.78 -21.21 -20.16 -16.36 -13.60

FRA:XE7C vs MNOV, PMVP, CING: E10 Comparison

For the Biotechnology subindustry, Cardiff Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Shiller PE Ratio falls into.


FRA:XE7C
31GF Score
Cardiff Oncology Inc FRA:XE7C
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.122/333.9520*333.9520
=-0.122

Current CPI (Jun. 2026) = 333.9520.

Cardiff Oncology Quarterly Data

per share eps CPI Adj_EPS
201609 -21.812 241.428 -30.171
201612 -23.207 241.432 -32.100
201703 -21.542 243.801 -29.508
201706 -16.661 244.955 -22.714
201709 -7.098 246.819 -9.604
201712 -3.650 246.524 -4.944
201803 -5.053 249.554 -6.762
201806 -4.511 251.989 -5.978
201809 -0.943 252.439 -1.247
201812 -0.958 251.233 -1.273
201903 -0.903 254.202 -1.186
201906 -0.673 256.143 -0.877
201909 -0.627 256.759 -0.816
201912 -0.459 256.974 -0.596
202003 -0.371 258.115 -0.480
202006 -0.453 257.797 -0.587
202009 -0.161 260.280 -0.207
202012 -0.148 260.474 -0.190
202103 -0.118 264.877 -0.149
202106 -0.141 271.696 -0.173
202109 -0.145 274.310 -0.177
202112 -0.204 278.802 -0.244
202203 -0.227 287.504 -0.264
202206 -0.227 296.311 -0.256
202209 -0.202 296.808 -0.227
202212 -0.189 296.797 -0.213
202303 -0.233 301.836 -0.258
202306 -0.231 305.109 -0.253
202309 -0.206 307.789 -0.224
202312 -0.193 306.746 -0.210
202403 -0.202 312.332 -0.216
202406 -0.242 314.175 -0.257
202409 -0.225 315.301 -0.238
202412 -0.201 315.605 -0.213
202503 -0.185 319.799 -0.193
202506 -0.182 322.561 -0.188
202509 -0.145 324.800 -0.149
202512 -0.094 324.054 -0.097
202603 -0.156 330.213 -0.158
202606 -0.122 333.952 -0.122

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-13.60 mean?
Cardiff Oncology (FRA:XE7C) has a E10 of €-13.60 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's E10 too high?
Cardiff Oncology's current E10 is €-13.60. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's E10 compare to MNOV and PMVP?
Cardiff Oncology's E10 of €-13.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current E10 is €-13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (FRA:XE7C) has a current E10 of €-13.60. The current E10 is €-13.60. Cardiff Oncology's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cardiff Oncology (FRA:XE7C), the current E10 is €-13.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges CRDF:USAXE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score

Get the complete analysis for FRA:XE7C

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price